» Articles » PMID: 15466982

Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: a Population-based Study

Overview
Date 2004 Oct 7
PMID 15466982
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Individual components of metabolic syndrome have been linked to an increased risk for prostate cancers. We hypothesized that metabolic syndrome itself could confer an increased risk for incident prostate cancer.

Methods: The participants were a population-based sample of 1,880 men from eastern Finland without history of cancer or diabetes mellitus at baseline.

Results: The metabolic syndrome (WHO criteria) was present in 357 (19%) of subjects. During an average follow-up of 13 years, a total of 183 cancers occurred, of which 56 were due to prostate cancer. The metabolic syndrome at baseline was related to a 1.9-fold (95% confidence interval, 1.1-3.5) risk of prostate cancer after adjustment for age, alcohol consumption, physical fitness, and energy, fat, fiber, calcium, vitamin E, and alpha-linolenic acid intake. The association between metabolic syndrome and risk of prostate cancer was stronger among overweight and obese men with a body mass index > or = 27 kg/m2 (adjusted relative risk, 3.0; 95% confidence interval, 1.2-7.3) than in lighter men (relative risk, 1.8; 95% confidence interval, 0.7-4.7).

Conclusions: Middle-aged men with the metabolic syndrome were more likely to develop prostate cancer in this prospective population-based study. This finding suggests that efforts to curb the epidemic of overweight and sedentary lifestyle and the accompanying metabolic syndrome may decrease the risk for prostate cancer.

Citing Articles

Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study.

Tran T, Lee J, Kim J, Kim S, Cho H, Kim J BMC Public Health. 2024; 24(1):3549.

PMID: 39707344 PMC: 11662620. DOI: 10.1186/s12889-024-20852-8.


Effect of metabolic syndrome on testosterone levels in patients with metastatic prostate cancer: a real-world retrospective study.

Zhuo T, Yao X, Mei Y, Yang H, Maimaitiyiming A, Huang X PeerJ. 2024; 12:e17823.

PMID: 39099654 PMC: 11298165. DOI: 10.7717/peerj.17823.


Association of Metabolic Syndrome with the Risk of Head and Neck Cancer: A 10-Year Follow-Up Study of 10 Million Initially Healthy Individuals.

Kim G, Han K, Joo Y Cancers (Basel). 2023; 15(16).

PMID: 37627146 PMC: 10452383. DOI: 10.3390/cancers15164118.


Association between body mass index, metabolic syndrome and common urologic conditions: a cross-sectional study using a large multi-institutional database from the United States.

Suarez Arbelaez M, Nackeeran S, Shah K, Blachman-Braun R, Bronson I, Towe M Ann Med. 2023; 55(1):2197293.

PMID: 37036830 PMC: 10088970. DOI: 10.1080/07853890.2023.2197293.


Role of Metabolism and Metabolic Pathways in Prostate Cancer.

Wanjari U, Mukherjee A, Gopalakrishnan A, Murali R, Dey A, Vellingiri B Metabolites. 2023; 13(2).

PMID: 36837801 PMC: 9962346. DOI: 10.3390/metabo13020183.